A Phase 3 interventional study of Denosumab and Placebo in Cancer, Cataract and Low Bone Mineral Density, sponsored by Amgen. Completed at 172 sites in 18 countries. Open to male participants aged 30 Years to 120 Years. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by Amgen · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing denosumab in Prostatic Neoplasms — none open to participants now, none under way, none of them phase 3. Denosumab · Prostatic Neoplasms.
Among the 10 studies testing denosumab in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2009, is one of 8 in phase 3, and was the 4th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →None of the 10 studies testing denosumab in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 30 Years to 120 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 769 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 324 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
23 studies in Prostatic Neoplasms by Amgen: 4 open now, 7 under way, 2 of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2009, is one of 9 in phase 3, and was the 9th registered.
Amgen’s Prostatic Neoplasms studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing denosumab in Prostatic Neoplasms, from their registry updates:
Among Amgen’s 23 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation therapy.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
This study's enrollment of 769 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Prostatic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo administered by subcutaneous injection on Day 1 and at Month 6.
Biological: Placebo
Participants received denosumab 60 mg administered by subcutaneous injection on Day 1 and at Month 6.
Biological: Denosumab
Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg
Also known as: Prolia®
Prefilled syringe for subcutaneous (SC) injection
Percentage of Participants With Lens Opacification Event Development or Progression by Month 12
The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline.
Time frame: 12 months
Percentage of Participant With Lens Opacification Event Development or Progression by Month 12 Based on a Change of ≥ 1.5 in P, ≥ 1.5 in C, or ≥ 1.5 in NO in the LOCS III Score
The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change ≥ 1.5 in P, ≥ 1.5 in C, or ≥ 1.5 in NO in the LOCS III score from baseline.
Time frame: 12 months
Percentage of Participants With Lens Opacification Event Development or Progression by Month 6
The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 6 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline.
Time frame: 6 months
Percentage of Participants With Confirmed Lens Opacification Event Development or Progression by Month 12
The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline. A confirmed lens opacification event development or progression was defined as 2 directly subsequent events per protocol assessments at the same location (P, C, NO) using LOCS III as above.
Time frame: 12 months
Percentage of Participants With a Decrease From Baseline in Best Corrected Visual Acuity (BCVA) of ≥ 10 Letters
The best corrected visual acuity (BCVA) is the best vision one can achieve with correction (such as eye glasses) as measured on an eye chart. BCVA was assessed by a trained ophthalmologist using the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart at 4 meters. The modified University of Crete ETDRS chart was used in Ukraine, Greece, Russia and Bulgaria, which do not use the Roman alphabet. The 2000 series revised ETDRS chart was used to assess the change in all other countries. The letter score was calculated based on the number of letters that were correctly identified; higher letter scores correspond to better visual acuity.
Time frame: Baseline and Months 3, 6, 9 and 12
Change From Baseline in Refraction Needed to Achieve BCVA
Refraction error was measured using a phoropter. The change from baseline in spherical refraction error needed to achieve BCVA is reported.
Time frame: Baseline and months 3, 6, 9, and 12
Number of Participants With Adverse Events
Adverse events (AEs) were assessed for severity by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) severity grading scale, version 3.0, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, Grade 4 =Life-threatening AE and Grade 5 = Death due to AE. Treatment-related AEs (TRAEs) include only events for which the investigator indicated there was a reasonable possibility they may have been caused by the study drug.
Time frame: 12 months
This study was conducted at 125 centers in 18 countries: Australia, Bulgaria, Canada, the Czech Republic, France, Greece, Hungary, India, Latvia, Mexico, New Zealand, Poland, Russia, Slovakia, Slovenia, South Africa, Ukraine, and the United States. The first participant enrolled on 30 November 2009 and the last participant enrolled on 04 May 2015.
| Milestone | Placebo | Denosumab |
|---|---|---|
| Started | 386 | 383 |
| Received treatment | 383 | 382 |
| Completed | 354 | 355 |
| Not completed | 32 | 28 |
| Withdrew: Withdrawal by subject | 16 | 14 |
| Withdrew: Death | 4 | 3 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Disease progression | 1 | 3 |
| Withdrew: Administrative decision | 1 | 1 |
| Withdrew: Noncompliance | 2 | 0 |
| Withdrew: Ineligibility determined | 2 | 0 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Requirement for alternative therapy | 0 | 1 |
| Withdrew: Other | 3 | 1 |
| Withdrew: Adverse event | 1 | 2 |
The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline.
| percentage of participants | Placebo | Denosumab |
|---|---|---|
| Percentage of Participants With Lens Opacification Event Development or Progression by Month 12 | 33.2 | 33.5 |
The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change ≥ 1.5 in P, ≥ 1.5 in C, or ≥ 1.5 in NO in the LOCS III score from baseline.
| percentage of participants | Placebo | Denosumab |
|---|---|---|
| Percentage of Participant With Lens Opacification Event Development or Progression by Month 12 Based on a Change of ≥ 1.5 in P, ≥ 1.5 in C, or ≥ 1.5 in NO in the LOCS III Score | 10.7 | 8.4 |
The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 6 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline.
| percentage of participants | Placebo | Denosumab |
|---|---|---|
| Percentage of Participants With Lens Opacification Event Development or Progression by Month 6 | 19.3 | 19.0 |
The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline. A confirmed lens opacification event development or progression was defined as 2 directly subsequent events per protocol assessments at the same location (P, C, NO) using LOCS III as above.
| percentage of participants | Placebo | Denosumab |
|---|---|---|
| Percentage of Participants With Confirmed Lens Opacification Event Development or Progression by Month 12 | 18.3 | 16.1 |
The best corrected visual acuity (BCVA) is the best vision one can achieve with correction (such as eye glasses) as measured on an eye chart. BCVA was assessed by a trained ophthalmologist using the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart at 4 meters. The modified University of Crete ETDRS chart was used in Ukraine, Greece, Russia and Bulgaria, which do not use the Roman alphabet. The 2000 series revised ETDRS chart was used to assess the change in all other countries. The letter score was calculated based on the number of letters that were correctly identified; higher letter scores correspond to better visual acuity.
| percentage of participants | Placebo | Denosumab |
|---|---|---|
| Month 3 (n = 372, 375) | 5.4 | 6.1 |
| Month 6 (n = 355, 357) | 4.2 | 6.4 |
| Month 9 (n = 350, 346) | 4.6 | 6.6 |
| Month 12 (n = 343, 342) | 5.2 | 7.3 |
Refraction error was measured using a phoropter. The change from baseline in spherical refraction error needed to achieve BCVA is reported.
| diopters | Placebo - Left Eye | Placebo - Right Eye | Denosumab | Denosumab - Right Eye |
|---|---|---|---|---|
| Month 3 (n = 362, 358, 358, 359) | 0.01 ± 0.60 | 0.01 ± 0.49 | 0.05 ± 0.73 | 0.04 ± 0.51 |
| Month 6 (n = 347, 343, 341, 344) | -0.01 ± 0.80 | 0.06 ± 0.70 | 0.06 ± 0.90 | 0.04 ± 0.59 |
| Month 9 (n = 341, 339, 332, 332) | 0.00 ± 0.84 | 0.01 ± 0.73 | 0.04 ± 0.75 | 0.01 ± 0.62 |
| Month 12 (n = 336, 334, 328, 329) | -0.03 ± 0.70 | -0.04 ± 0.59 | 0.03 ± 0.77 | 0.00 ± 0.48 |
Adverse events (AEs) were assessed for severity by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) severity grading scale, version 3.0, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, Grade 4 =Life-threatening AE and Grade 5 = Death due to AE. Treatment-related AEs (TRAEs) include only events for which the investigator indicated there was a reasonable possibility they may have been caused by the study drug.
| participants | Placebo | Denosumab |
|---|---|---|
| Any adverse event | 193 | 191 |
| Serious adverse events | 52 | 42 |
| AE leading to discontinuation of study drug | 5 | 7 |
| AE leading to discontinuation from study | 2 | 4 |
| Fatal adverse events | 4 | 3 |
| AE grade 3, 4, or 5 | 53 | 46 |
| Treatment-related adverse events | 19 | 21 |
| Serious treatment-related adverse events | 1 | 2 |
| TRAE leading to discontinuation of study drug | 1 | 3 |
| TRAE leading to discontinuation from study | 0 | 1 |
| Fatal treatment-related adverse events | 0 | 0 |
| TRAE grade 3, 4, or 5 | 2 | 2 |
Collected over 12 months. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 52/380 (13.7%) | 107/380 (28.2%) |
| Denosumab | — | 42/385 (10.9%) | 121/385 (31.4%) |
| Event | Placebo | Denosumab |
|---|---|---|
| Cerebrovascular accidentNervous system disorders | 4/380 | 1/385 |
| Myocardial ischaemiaCardiac disorders | 1/380 | 3/385 |
| Coronary artery diseaseCardiac disorders | 2/380 | 1/385 |
| Myocardial infarctionCardiac disorders | 2/380 | 1/385 |
| DiarrhoeaGastrointestinal disorders | 2/380 | 0/385 |
| DiverticulitisInfections and infestations | 2/380 | 0/385 |
| PneumoniaInfections and infestations | 2/380 | 0/385 |
| DizzinessNervous system disorders | 2/380 | 0/385 |
| Acute kidney injuryRenal and urinary disorders | 2/380 | 0/385 |
| Urinary retentionRenal and urinary disorders | 2/380 | 0/385 |
| Event | Placebo | Denosumab |
|---|---|---|
| ConstipationGastrointestinal disorders | 16/380 | 8/385 |
| HypertensionVascular disorders | 16/380 | 8/385 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/380 | 12/385 |
| Back painMusculoskeletal and connective tissue disorders | 10/380 | 11/385 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 10/380 | 6/385 |
| NasopharyngitisInfections and infestations | 7/380 | 10/385 |
| Hot flushVascular disorders | 7/380 | 7/385 |
| Oedema peripheralGeneral disorders | 1/380 | 7/385 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/380 | 7/385 |
| PollakiuriaRenal and urinary disorders | 6/380 | 7/385 |
| Age, Continuous(years) | Placebo | Denosumab | Total |
|---|---|---|---|
| Mean | 71.0 ± 7.0 | 71.1 ± 7.2 | 71.0 ± 7.1 |
| Age, Customized(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| 18 - 64 years | 73 | 66 | 139 |
| 65 - 74 years | 189 | 194 | 383 |
| 75 - 84 years | 119 | 116 | 235 |
| ≥ 85 years | 5 | 7 | 12 |
| Sex: Female, Male(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 386 | 383 | 769 |
| Race/Ethnicity, Customized(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| White | 359 | 346 | 705 |
| Black (or African American) | 12 | 11 | 23 |
| Hispanic/Latino | 1 | 9 | 10 |
| Other | 7 | 8 | 15 |
| Asian | 7 | 7 | 14 |
| Japanese | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Presence of Cataract(s)(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Yes | 59 | 63 | 122 |
| No | 327 | 320 | 647 |
| Presence of Diabetes(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Yes | 70 | 61 | 131 |
| No | 316 | 322 | 638 |
| Received Androgen-deprivation Therapy (ADT)(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Yes | 350 | 353 | 703 |
| No | 36 | 30 | 66 |
| Orchiectomy (Surgical Castration)(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Yes | 58 | 51 | 109 |
| No | 328 | 332 | 660 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 172 sites across 18 countries. Choose a country and city above to see the rest.
Ran from Nov 2009 to primary completion in May 2016, 77 months.
Results were first posted in May 2017, 1 year after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 77 months is above that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab